类风湿关节炎的生物疗法：临床医生概述
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.
作者信息
Findeisen Kate E, Sewell Julia, Ostor Andrew J K
机构信息
The Alfred Hospital, Melbourne, Victoria, Australia.
Cabrini Medical Centre, Melbourne, Victoria, Australia.
出版信息
Biologics. 2021 Aug 12;15:343-352. doi: 10.2147/BTT.S252575. eCollection 2021.
Abstract
Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the "real-world" use of bDMARDs and how they fit into the overall RA treatment guidelines.
摘要
类风湿性关节炎（RA）是一种以滑膜关节炎症为特征的疾病，给个人和社会都带来了沉重的医疗负担。随着生物性疾病改善抗风湿药物（bDMARDs）的引入，RA治疗领域发生了最显著的转变之一。目前有五类bDMARDs可供使用，每类都有不同的分子靶点，其疗效和安全性也存在细微差异。本综述还描述了bDMARDs的“实际应用”以及它们如何融入整体RA治疗指南。
相似文献
1
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.类风湿关节炎的生物疗法：临床医生概述
Biologics. 2021 Aug 12;15:343-352. doi: 10.2147/BTT.S252575. eCollection 2021.
2
Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.类风湿关节炎患者使用或未使用生物性改善病情抗风湿药物时合并症与医疗保健消费的比较：一项基于登记的研究
BMC Musculoskelet Disord. 2016 Dec 12;17(1):499. doi: 10.1186/s12891-016-1354-7.
3
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.在一组接受生物改善病情抗风湿药或托法替布治疗的类风湿关节炎患者中医疗资源的使用情况。
Clin Rheumatol. 2021 Apr;40(4):1273-1281. doi: 10.1007/s10067-020-05432-6. Epub 2020 Sep 30.
4
Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.抗核抗体的产生与类风湿关节炎患者对生物改善病情抗风湿药物治疗反应不良有关。
Semin Arthritis Rheum. 2019 Oct;49(2):204-210. doi: 10.1016/j.semarthrit.2019.02.003. Epub 2019 Feb 10.
5
Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.马来西亚类风湿关节炎患者使用生物改善病情抗风湿药物的真实世界临床经验。
Rheumatol Int. 2017 Oct;37(10):1719-1725. doi: 10.1007/s00296-017-3772-8. Epub 2017 Jul 10.
6
Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs): Results of 3 to 4 years of follow-up.生物制剂治疗类风湿关节炎患者大关节损伤影像学进展的预测因素：3 至 4 年随访结果。
Mod Rheumatol. 2019 Nov;29(6):903-909. doi: 10.1080/14397595.2018.1532544. Epub 2019 Jan 3.
7
Real-world experience with tofacitinib for the treatment of rheumatoid arthritis.托法替布治疗类风湿关节炎的真实世界经验。
Clin Exp Rheumatol. 2019 May-Jun;37(3):485-495. Epub 2018 Aug 29.
8
9
Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.老年类风湿关节炎患者在临床实践中对生物性改善病情抗风湿药物的严重药物不良反应
Clin Exp Rheumatol. 2018 Jan-Feb;36(1):29-35. Epub 2017 Jun 6.
10
Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.联合治疗预防类风湿关节炎骨损伤的疗效与安全性。
Clin Rheumatol. 2016 Jan;35(1):19-23. doi: 10.1007/s10067-015-3120-x. Epub 2015 Nov 19.
引用本文的文献
1
Looking to the new horizon in rheumatology research.展望风湿病学研究的新前景。
Nat Rev Rheumatol. 2025 Aug 14. doi: 10.1038/s41584-025-01295-w.
2
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?生物类似药市场渗透中的需求侧与供给侧政策：哪种更有效？
BioDrugs. 2025 May 9. doi: 10.1007/s40259-025-00721-5.
3
The Dental Status of Patients Taking Common Biologic Agents: A Single-Center Cross-Sectional Study.服用常见生物制剂患者的口腔状况：一项单中心横断面研究。
Oral Dis. 2025 Aug;31(8):2641-2651. doi: 10.1111/odi.15311. Epub 2025 Mar 17.
4
STAT3 phosphorylation in the rheumatoid arthritis immunological synapse.类风湿关节炎免疫突触中的信号转导和转录激活因子3（STAT3）磷酸化
bioRxiv. 2025 Jan 22:2025.01.20.633875. doi: 10.1101/2025.01.20.633875.
5
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.度维利塞是一种新型的NFAT抑制剂，可减轻阿达木单抗诱导的免疫原性。
Front Pharmacol. 2025 Jan 9;15:1397995. doi: 10.3389/fphar.2024.1397995. eCollection 2024.
6
Transcriptomic Analysis of Blood Collagen-Induced Arthritis Mice Exposed to 0.1 THz Reveals Inhibition of Genes and Pathways Involved in Rheumatoid Arthritis.对暴露于0.1太赫兹的血液胶原蛋白诱导性关节炎小鼠进行转录组分析，揭示了类风湿性关节炎相关基因和通路的抑制作用。
Int J Mol Sci. 2024 Nov 28;25(23):12812. doi: 10.3390/ijms252312812.
7
Monoclonal antibodies: From magic bullet to precision weapon.单克隆抗体：从“魔弹”到“精准武器”。
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
8
Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas.免疫学与微生物学研究进展：关键领域的全面探索
Microorganisms. 2024 Aug 14;12(8):1672. doi: 10.3390/microorganisms12081672.
9
A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor.在初始肿瘤坏死因子抑制剂转换后，接受乌帕替尼、肿瘤坏死因子抑制剂和其他先进疗法治疗的类风湿关节炎患者的临床疗效的真实世界比较。
Adv Ther. 2024 Sep;41(9):3706-3721. doi: 10.1007/s12325-024-02948-0. Epub 2024 Aug 7.
10
Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis.类风湿关节炎患者接受利妥昔单抗治疗反应的常规临床实践中的早期预测因素。
Reumatologia. 2024;62(3):150-156. doi: 10.5114/reum/189780. Epub 2024 Jun 18.
本文引用的文献
1
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2021 年美国风湿病学会类风湿关节炎治疗指南。
Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8.
2
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
3
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.美国风湿病学会关于风湿性和肌肉骨骼疾病患者接种新冠病毒疫苗的指南：第1版
Arthritis Rheumatol. 2021 Jul;73(7):1093-1107. doi: 10.1002/art.41734. Epub 2021 May 24.
4
TNF in the era of immune checkpoint inhibitors: friend or foe?免疫检查点抑制剂时代的肿瘤坏死因子：是友还是敌？
Nat Rev Rheumatol. 2021 Apr;17(4):213-223. doi: 10.1038/s41584-021-00584-4. Epub 2021 Mar 8.
5
Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage.类风湿关节炎的免疫抑制剂：临床试验及其当前发展阶段的系统评价
Ther Adv Musculoskelet Dis. 2020 Dec 16;12:1759720X20959971. doi: 10.1177/1759720X20959971. eCollection 2020.
6
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.美国风湿病学会在 COVID-19 大流行期间成人患者风湿病管理指南：第 3 版。
Arthritis Rheumatol. 2021 Feb;73(2):e1-e12. doi: 10.1002/art.41596. Epub 2020 Dec 5.
7
The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review.类风湿关节炎的全球患病率：基于系统综述的荟萃分析。
Rheumatol Int. 2021 May;41(5):863-877. doi: 10.1007/s00296-020-04731-0. Epub 2020 Nov 11.
8
The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence.在不断发展的多种生物类似药领域中切换治疗方案的挑战：当前证据的叙述性综述。
Adv Ther. 2020 Nov;37(11):4491-4518. doi: 10.1007/s12325-020-01472-1. Epub 2020 Sep 10.
9
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.我们如何在有恶性肿瘤病史的类风湿性关节炎患者中使用生物制剂？使用斯堪的纳维亚登记册对治疗模式进行评估。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001363.
10
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.类风湿关节炎患者中生物制剂初治和转换治疗患者中 7 种生物制剂和托法替布的药物保留率：ANSWER 队列研究。
Arthritis Res Ther. 2020 Jun 15;22(1):142. doi: 10.1186/s13075-020-02232-w.
Zotero 插件